Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro

Viki B. Swope, Andrew P. Supp, David G Greenhalgh, Glenn D. Warden, Steven T. Boyce

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Clinical efficacy of cultured skin substitutes may be increased if their carbohydrate metabolism is optimized by understanding whether endogenous insulin-like growth factor I can substitute for exogenous insulin. Cultured skin substitutes were prepared and incubated at the air-liquid interface for 4 wk in media containing 0.5 or 5 μg per ml insulin, 10 or 50 ng per ml insulin-like growth factor I, or 0 insulin and 0 insulin-like growth factor I (negative control). In situ hybridization showed that the epidermal and dermal cultured skin substitute components express insulin-like growth factor I mRNA throughout the 28 d interval. Immunohistochemistry confirmed the expression of insulin-like growth factor I protein by the human keratinocytes and fibroblasts in cultured skin substitutes. Insulin-like growth factor I at 10 or 30 ng per ml could partially replace insulin in a clonal assay of keratinocyte growth. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays showed significantly higher values in cultured skin substitutes incubated with insulin at incubation days 14 and 28 compared to negative control or the 10 ng per ml insulin-like growth factor I condition. Cultured skin substitutes incubated in 50 ng per ml insulin-like growth factor I had MTT values similar to the insulin-treated cultured skin substitutes at day 14, but were significantly lower by day 28. Light microscopy agreed with MTT data showing that cultured skin substitutes grown with insulin media had multiple layers of nucleated keratinocytes and stratum corneum at days 14 and 28. The negative control and 10 ng per ml insulin-like growth factor I exhibited poor cultured skin substitute epidermal morphology throughout the experiment. In contrast, the cultured skin substitutes in 50 ng per ml insulin-like growth factor I were similar to the insulin-treated cultured skin substitutes at day 14, but by day 28 had deteriorated to resemble the negative control. Bromodeoxyuridine incorporation at day 28 was significantly higher for 5 μg per ml insulin cultured skin substitutes versus all other treatment groups. These data suggest that medium containing 5 μg per ml insulin supports greater physiologic stability in cultured skin substitutes over time, and that expression of insulin-like growth factor I by keratinocytes and fibroblasts in cultured skin substitutes is not sufficient to fully replace the requirement for exogenous insulin in vitro.

Original languageEnglish (US)
Pages (from-to)650-657
Number of pages8
JournalJournal of Investigative Dermatology
Volume116
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Artificial Skin
Insulin-Like Growth Factor I
Insulin
Keratinocytes
Fibroblasts
In Vitro Techniques
Assays
Carbohydrate Metabolism
Bromodeoxyuridine

Keywords

  • DNA synthesis
  • Epidermal barrier
  • Fibroblasts
  • Keratinocytes
  • Wound healing

ASJC Scopus subject areas

  • Dermatology

Cite this

Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro. / Swope, Viki B.; Supp, Andrew P.; Greenhalgh, David G; Warden, Glenn D.; Boyce, Steven T.

In: Journal of Investigative Dermatology, Vol. 116, No. 5, 2001, p. 650-657.

Research output: Contribution to journalArticle

@article{6df96f59c5c54cc4b65f06c7e6c4ec78,
title = "Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro",
abstract = "Clinical efficacy of cultured skin substitutes may be increased if their carbohydrate metabolism is optimized by understanding whether endogenous insulin-like growth factor I can substitute for exogenous insulin. Cultured skin substitutes were prepared and incubated at the air-liquid interface for 4 wk in media containing 0.5 or 5 μg per ml insulin, 10 or 50 ng per ml insulin-like growth factor I, or 0 insulin and 0 insulin-like growth factor I (negative control). In situ hybridization showed that the epidermal and dermal cultured skin substitute components express insulin-like growth factor I mRNA throughout the 28 d interval. Immunohistochemistry confirmed the expression of insulin-like growth factor I protein by the human keratinocytes and fibroblasts in cultured skin substitutes. Insulin-like growth factor I at 10 or 30 ng per ml could partially replace insulin in a clonal assay of keratinocyte growth. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays showed significantly higher values in cultured skin substitutes incubated with insulin at incubation days 14 and 28 compared to negative control or the 10 ng per ml insulin-like growth factor I condition. Cultured skin substitutes incubated in 50 ng per ml insulin-like growth factor I had MTT values similar to the insulin-treated cultured skin substitutes at day 14, but were significantly lower by day 28. Light microscopy agreed with MTT data showing that cultured skin substitutes grown with insulin media had multiple layers of nucleated keratinocytes and stratum corneum at days 14 and 28. The negative control and 10 ng per ml insulin-like growth factor I exhibited poor cultured skin substitute epidermal morphology throughout the experiment. In contrast, the cultured skin substitutes in 50 ng per ml insulin-like growth factor I were similar to the insulin-treated cultured skin substitutes at day 14, but by day 28 had deteriorated to resemble the negative control. Bromodeoxyuridine incorporation at day 28 was significantly higher for 5 μg per ml insulin cultured skin substitutes versus all other treatment groups. These data suggest that medium containing 5 μg per ml insulin supports greater physiologic stability in cultured skin substitutes over time, and that expression of insulin-like growth factor I by keratinocytes and fibroblasts in cultured skin substitutes is not sufficient to fully replace the requirement for exogenous insulin in vitro.",
keywords = "DNA synthesis, Epidermal barrier, Fibroblasts, Keratinocytes, Wound healing",
author = "Swope, {Viki B.} and Supp, {Andrew P.} and Greenhalgh, {David G} and Warden, {Glenn D.} and Boyce, {Steven T.}",
year = "2001",
doi = "10.1046/j.1523-1747.2001.01325.x",
language = "English (US)",
volume = "116",
pages = "650--657",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro

AU - Swope, Viki B.

AU - Supp, Andrew P.

AU - Greenhalgh, David G

AU - Warden, Glenn D.

AU - Boyce, Steven T.

PY - 2001

Y1 - 2001

N2 - Clinical efficacy of cultured skin substitutes may be increased if their carbohydrate metabolism is optimized by understanding whether endogenous insulin-like growth factor I can substitute for exogenous insulin. Cultured skin substitutes were prepared and incubated at the air-liquid interface for 4 wk in media containing 0.5 or 5 μg per ml insulin, 10 or 50 ng per ml insulin-like growth factor I, or 0 insulin and 0 insulin-like growth factor I (negative control). In situ hybridization showed that the epidermal and dermal cultured skin substitute components express insulin-like growth factor I mRNA throughout the 28 d interval. Immunohistochemistry confirmed the expression of insulin-like growth factor I protein by the human keratinocytes and fibroblasts in cultured skin substitutes. Insulin-like growth factor I at 10 or 30 ng per ml could partially replace insulin in a clonal assay of keratinocyte growth. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays showed significantly higher values in cultured skin substitutes incubated with insulin at incubation days 14 and 28 compared to negative control or the 10 ng per ml insulin-like growth factor I condition. Cultured skin substitutes incubated in 50 ng per ml insulin-like growth factor I had MTT values similar to the insulin-treated cultured skin substitutes at day 14, but were significantly lower by day 28. Light microscopy agreed with MTT data showing that cultured skin substitutes grown with insulin media had multiple layers of nucleated keratinocytes and stratum corneum at days 14 and 28. The negative control and 10 ng per ml insulin-like growth factor I exhibited poor cultured skin substitute epidermal morphology throughout the experiment. In contrast, the cultured skin substitutes in 50 ng per ml insulin-like growth factor I were similar to the insulin-treated cultured skin substitutes at day 14, but by day 28 had deteriorated to resemble the negative control. Bromodeoxyuridine incorporation at day 28 was significantly higher for 5 μg per ml insulin cultured skin substitutes versus all other treatment groups. These data suggest that medium containing 5 μg per ml insulin supports greater physiologic stability in cultured skin substitutes over time, and that expression of insulin-like growth factor I by keratinocytes and fibroblasts in cultured skin substitutes is not sufficient to fully replace the requirement for exogenous insulin in vitro.

AB - Clinical efficacy of cultured skin substitutes may be increased if their carbohydrate metabolism is optimized by understanding whether endogenous insulin-like growth factor I can substitute for exogenous insulin. Cultured skin substitutes were prepared and incubated at the air-liquid interface for 4 wk in media containing 0.5 or 5 μg per ml insulin, 10 or 50 ng per ml insulin-like growth factor I, or 0 insulin and 0 insulin-like growth factor I (negative control). In situ hybridization showed that the epidermal and dermal cultured skin substitute components express insulin-like growth factor I mRNA throughout the 28 d interval. Immunohistochemistry confirmed the expression of insulin-like growth factor I protein by the human keratinocytes and fibroblasts in cultured skin substitutes. Insulin-like growth factor I at 10 or 30 ng per ml could partially replace insulin in a clonal assay of keratinocyte growth. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays showed significantly higher values in cultured skin substitutes incubated with insulin at incubation days 14 and 28 compared to negative control or the 10 ng per ml insulin-like growth factor I condition. Cultured skin substitutes incubated in 50 ng per ml insulin-like growth factor I had MTT values similar to the insulin-treated cultured skin substitutes at day 14, but were significantly lower by day 28. Light microscopy agreed with MTT data showing that cultured skin substitutes grown with insulin media had multiple layers of nucleated keratinocytes and stratum corneum at days 14 and 28. The negative control and 10 ng per ml insulin-like growth factor I exhibited poor cultured skin substitute epidermal morphology throughout the experiment. In contrast, the cultured skin substitutes in 50 ng per ml insulin-like growth factor I were similar to the insulin-treated cultured skin substitutes at day 14, but by day 28 had deteriorated to resemble the negative control. Bromodeoxyuridine incorporation at day 28 was significantly higher for 5 μg per ml insulin cultured skin substitutes versus all other treatment groups. These data suggest that medium containing 5 μg per ml insulin supports greater physiologic stability in cultured skin substitutes over time, and that expression of insulin-like growth factor I by keratinocytes and fibroblasts in cultured skin substitutes is not sufficient to fully replace the requirement for exogenous insulin in vitro.

KW - DNA synthesis

KW - Epidermal barrier

KW - Fibroblasts

KW - Keratinocytes

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=0034999854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034999854&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1747.2001.01325.x

DO - 10.1046/j.1523-1747.2001.01325.x

M3 - Article

C2 - 11348451

AN - SCOPUS:0034999854

VL - 116

SP - 650

EP - 657

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 5

ER -